Company news

DiaMedica Therapeutics Inc. news in 2024

DiaMedica Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

December 2, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

November 12, 2024

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

November 12, 2024

DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference

November 11, 2024

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

November 5, 2024

DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia

October 8, 2024

DiaMedica Therapeutics Upcoming Conference Participation

September 3, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results

August 6, 2024

DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

July 31, 2024

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

July 10, 2024

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement

June 30, 2024

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia

June 25, 2024

DiaMedica Therapeutics Announces $11.8 Million Private Placement

June 25, 2024

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results

May 7, 2024

DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024

May 1, 2024

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

April 16, 2024

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

March 18, 2024

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

January 28, 2024

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

January 21, 2024

Calls in 2024

Decks in 2024